- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04814485
Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer
A Prospective, Single-center Clinical Study to Explore the Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This trial is a prospective, single-center, single-arm clinical research. Advanced pancreatic cancer is an aggressive disease with extremely low 5-year survival rate. For advanced pancreatic cancer patients who failed with first-line treatment, subsequent treatment options are limited. SHR-1020 combined with albumin-bound paclitaxel could through multiple mechanisms such as block tumor mitosis, inhibit tumor angiogenesis, inhibit interstitial fibrosis to achieve anti-tumor effect.
The safety and efficacy of this study will be assessed through ORR, DCR,PFS, OS , and adverse effects as graded by CTCAE 5.0.
Studietype
Registrering (Forventet)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Tianjin
-
Tianjin, Tianjin, Kina, 300000
- Rekruttering
- Tianjin Medical University Cancer Institute and Hospital
-
Ta kontakt med:
- jihui Hao, MD
- Telefonnummer: 022-23524155
- E-post: ec_tjcih@126.com
-
Ta kontakt med:
- chuntao Gao, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Patients who were diagnosed as metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma by histopathology or cytology, at least one measurable lesion conforming to RECIST 1.1 criteria.
- Disease progresses or intolerance for first-line standard treatment, including patients who relapsed or metastasized within 6 months of neoadjuvant or adjuvant therapy
- ECOG score 0-2
- Adequate organ and bone marrow function
- The expected survival time is ≥ 12 weeks
- Had normal swallowing function, without dysfunction of gastrointestinal absorption
- Willing to consent and signed the informed consent, and able comply with the planned visit, research treatment, laboratory examination and other test procedures
Exclusion Criteria:
- The patient has previously received anti-angiogenic drugs or albumin-bound paclitaxel;
- The first study drug treatment was less than 2 weeks or 5 half-lives (in terms of longer) from the last chemotherapy or 5 half-lives from the last targeted therapy
- Known to be allergic to the active ingredients or excipients in this study.
- Had other active malignant tumors within 5 years before entering the study.
- Subject with cerebral metastasis
- Have a clear history of serious and uncontrolled other disease or mental disorders;
- Other chemotherapy, targeted therapy, hormonotherapy, immunotherapy, radiotherapy or traditional Chinese medicine should be used for anti-tumor therapy
- Other situations that the researcher considers inappropriate to participate in the research.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: SHR-1020 combined with albumin-bound paclitaxel
|
SHR-1020 combined with albumin-bound paclitaxel for advanced pancreatic cancer
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
ORR (Objective Response Rate)
Tidsramme: From date of first dose until the date of first documented progression or date of death from any cause, whichever came first,assessed up to 12 months]
|
Containing the incidence of complete response (CR) and partial response (PR).
Evaluated according to RECIST 1.1 criteria,subjects received their first tumor imaging evaluation at 8 weeks after the treatment start, followed by imaging evaluation every 2 cycles.
|
From date of first dose until the date of first documented progression or date of death from any cause, whichever came first,assessed up to 12 months]
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
DCR (Disease Control Rate)
Tidsramme: From date of first dose until the date of first documented progression or date of death from any cause, whichever came first,assessed up to 12 months]
|
Containing the incidence of complete response (CR), partial response (PR) and stable disease (SD).Evaluated according to RECIST 1.1 criteria,subjects received their first tumor imaging evaluation at 8 weeks after the treatment start, followed by imaging evaluation every 2 cycles.
|
From date of first dose until the date of first documented progression or date of death from any cause, whichever came first,assessed up to 12 months]
|
PFS (Progression-Free-Survival)
Tidsramme: From date of treatment start until the date of progression or the date of death due to any caus, assessed up to 12 months
|
From date of treatment start until the date of progression or the date of death due to any cause.Evaluated according to RECIST 1.1 criteria,subjects received their first tumor imaging evaluation at 8 weeks after the treatment start, followed by imaging evaluation every 2 cycles.
|
From date of treatment start until the date of progression or the date of death due to any caus, assessed up to 12 months
|
6mPFS
Tidsramme: Up to 6 months
|
6-month- Progression-Free-Survival rate.
Evaluated according to RECIST 1.1 criteria,subjects received their first tumor imaging evaluation at 8 weeks after the treatment start, followed by imaging evaluation every 2 cycles.
|
Up to 6 months
|
OS (overall survival)
Tidsramme: From date of treatment start until the date of death from any cause or censored at the last day that the patient is documented to be alive, whichever came first, assessed up to 12 months
|
From date of treatment start to any cause death or last follow-up.
|
From date of treatment start until the date of death from any cause or censored at the last day that the patient is documented to be alive, whichever came first, assessed up to 12 months
|
Adverse events (per CTCAE v5.0 criteria)
Tidsramme: Up to 12months
|
To evaluate the adverse events of patients with advanced pancreatic cancer after treated with SHR-1020 plus albumin-bound paclitaxel
|
Up to 12months
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sykdommer i fordøyelsessystemet
- Neoplasmer
- Neoplasmer etter nettsted
- Sykdommer i det endokrine systemet
- Neoplasmer i fordøyelsessystemet
- Neoplasmer i endokrine kjertel
- Pankreassykdommer
- Neoplasmer i bukspyttkjertelen
- Molekylære mekanismer for farmakologisk virkning
- Antineoplastiske midler
- Tubulin modulatorer
- Antimitotiske midler
- Mitosemodulatorer
- Antineoplastiske midler, fytogene
- Paklitaksel
- Albuminbundet paklitaksel
Andre studie-ID-numre
- PANC-2nd-IIT-FMTN-naP
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Bukspyttkjertelkreft
-
Tianjin Medical University Cancer Institute and...Har ikke rekruttert ennåPDAC - Pancreatic Ductal Adenocarcinoma
-
Sun Yat-sen UniversityRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaKina
-
Azienda Ospedaliera Universitaria Integrata VeronaRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaItalia
-
Azienda Ospedaliera Universitaria Integrata VeronaRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaItalia
-
Cedars-Sinai Medical CenterRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaForente stater
-
Radboud University Medical CenterDutch Cancer SocietyRekrutteringPDAC - Pancreatic Ductal AdenocarcinomaNederland
-
Thomas Jefferson UniversityUkjentBukspyttkjertelfistel | Distal pankreatektomikomplikasjoner | Falciform Patch Pancreatic Closure | Fibrinlim bukspyttkjertellukkingForente stater
-
Imperial College LondonThe Leeds Teaching Hospitals NHS Trust; Sheffield Teaching Hospitals NHS... og andre samarbeidspartnereRekrutteringBukspyttkjertelkreft | PDAC - Pancreatic Ductal AdenocarcinomaStorbritannia
-
Chinese PLA General HospitalRekrutteringNeoplasmer i bukspyttkjertelen | Bukspyttkjertelkreft | Bukspyttkjertelkreft | PDAC - Pancreatic Ductal AdenocarcinomaKina
-
Andrei IagaruIkke lenger tilgjengeligKarsinoide svulster | Islet Cell (Pancreatic NET) | Andre nevroendokrine svulsterForente stater
Kliniske studier på SHR-1020+albumin-bound paclitaxel
-
China Medical University, ChinaUkjent
-
Qian ChuJiangsu HengRui Medicine Co., Ltd.Rekruttering
-
Jiangsu HengRui Medicine Co., Ltd.Har ikke rekruttert ennåNasofaryngealt karsinomKina
-
Tianjin Medical University Cancer Institute and...Har ikke rekruttert ennåEsophageal plateepitelkarsinom | Progresjon til PD-1 antistoffKina
-
Junling LiUkjentSmåcellet lungekreft i omfattende stadiumKina
-
Peking UniversityFullførtGastrisk adenokarsinomKina
-
Jiangsu HengRui Medicine Co., Ltd.RekrutteringIkke-småcellet lungekreftKina
-
City of Hope Medical CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeTilbakevendende brystkarsinom | Stage IV brystkreft AJCC v6 og v7 | Stage III brystkreft AJCC v7 | Stage IIIA brystkreft AJCC v7 | Stage IIIB brystkreft AJCC v7 | Stage IIIC brystkreft AJCC v7 | Metastatisk brystkarsinom | Lokalt avansert brystkarsinomForente stater
-
Anne NoonanNational Cancer Institute (NCI)RekrutteringStage IV Bukspyttkjertelkreft AJCC v8 | Metastatisk bukspyttkjerteladenokarsinomForente stater
-
Mayo ClinicNational Cancer Institute (NCI)TilbaketrukketTilbakevendende blære urotelialt karsinom | Stadium IV blære urotelialt karsinomForente stater